Autophagy-Lysosomal Pathway in Parkinson’s Disease

Overview

The autophagy-lysosomal pathway (ALP) is a core proteostasis system in neurons. It clears long-lived proteins, damaged organelles, and toxic aggregates through coordinated macroautophagy, chaperone-mediated autophagy (CMA), endolysosomal trafficking, and lysosomal proteolysis.[@menzies2015][@dehay2013] In Parkinson’s disease, ALP failure amplifies accumulation of alpha-synuclein, blocks mitochondrial quality control, and drives progressive vulnerability of substantia nigra pars compacta neurons.[@sidransky2009][@pickrell2015]

The strongest human-genetic evidence comes from lysosomal genes: GBA, LRRK2, ATP13A2, VPS35, and TMEM175.[@sidransky2009][@blauwendraat2020][@usenovic2012] Convergent neuropathology and biomarker studies indicate that ALP dysfunction is not an isolated secondary effect; it is a central disease axis that feeds forward into synucleinopathy, neuroinflammation, and bioenergetic collapse.[@dehay2013][@tan2020]

Autophagy-Lysosomal Pathway Proteins Comparison

Key autophagy proteins and their involvement in Parkinson’s disease:

Protein/Process	Gene	Function in ALP	PD Association	Mutations in PD	Therapeutic Target
mTOR	MTOR	Master regulator of autophagy	Hyperactive (inhibits autophagy)	Risk variant	mTOR inhibitors
ULK1/2	ULK1/ULK2	Initiation complex	Dysregulated	Risk variants	ULK1 activators
Beclin-1	BECN1	Autophagy initiation	Decreased	Not common	BECN1 agonists
LC3	MAP1LC3A/B	Autophagosome formation	Reduced	N/A	LC3 modulators
p62/SQSTM1	SQSTM1	Selective autophagy receptor	Accumulates	Mutations cause PDB	p62 modulators
LAMP-2	LAMP2	Lysosomal membrane	Defective	Danon disease	LAMP-2 enhancement
GBA	GBA	Lysosomal enzyme (glucocerebrosidase)	Reduced activity	Major risk factor	GBA enhancers
ATP13A2	ATP13A2	Lysosomal ATPase	Loss of function	Kufor-Rakeb	ATP13A2 restoration
Parkin	PRKN	Mitophagy E3 ligase	Dysfunctional	Familial PD	Parkin activators
PINK1	PINK1	Mitophagy kinase	Dysfunctional	Familial PD	PINK1 activators
DJ-1	PARK7	Mitophagy regulation	Oxidized/inactive	Familial PD	DJ-1 stabilizers
TFEB	TFEB	ALP transcription factor	Nuclear translocation blocked	N/A	TFEB activators

Autophagy subtypes in PD:

Macroautophagy: General autophagy - impaired in PD
Mitophagy: Mitochondrial-specific - Parkin/PINK1 pathway defective
CMA: Chaperone-mediated - LAMP-2A deficient
Endolysosomal: GBA and ATP13A2 defects

Mechanistic Map

Core ALP Modules

1) Macroautophagy initiation and cargo delivery

Neuronal macroautophagy starts with ULK1 complex activation and Beclin1-VPS34 lipid signaling, followed by ATG conjugation systems that build LC3-decorated autophagosomes.[@menzies2015][@noda2015] In PD, autophagosome accumulation is often interpreted as increased autophagy, but flux studies show many cells fail at later fusion/degradation steps, producing a net clearance deficit.[@dehay2013][@chu2009]

Key consequences:

Increased LC3-II and p62/SQSTM1 can represent blocked turnover rather than successful clearance.[@dehay2013][@chu2009]
Neurons with long axons are especially vulnerable because impaired retrograde transport delays autophagosome delivery to somatic lysosomes.[@maday2014]

2) Chaperone-mediated autophagy (CMA)

CMA selectively imports KFERQ-motif proteins through LAMP2A and Hsc70. Wild-type alpha-synuclein can be cleared by CMA, but pathogenic and post-translationally modified species bind the translocation machinery and inhibit their own clearance.[@cuervo2004][@martinezvicente2008] This converts CMA from a protective route into a bottleneck that increases toxic oligomer burden.

3) Lysosomal function and acidification

Lysosomal hydrolases require low pH and intact membrane ion homeostasis. PD-linked variants in GBA and TMEM175 disrupt this environment, reducing substrate degradation and promoting glucosylceramide/sphingolipid imbalance that stabilizes alpha-synuclein oligomers.[@sidransky2009][@blauwendraat2020][@mazzulli2011] ATP13A2 loss also impairs lysosomal cation handling and autophagosome-lysosome function.[@usenovic2012]

4) Endolysosomal trafficking

Retromer and endosomal regulators route membrane proteins and hydrolases to correct compartments. VPS35 dysfunction and LRRK2-driven Rab dysregulation impair vesicle sorting, contributing to lysosomal substrate overload and defective receptor recycling.[@zavodszky2014][@bonetponce2019]

Feed-Forward Loops Driving Disease Progression

GBA-alpha-synuclein bidirectional loop

Reduced GCase activity increases glucosylceramide species that favor toxic alpha-synuclein conformers. Accumulated alpha-synuclein then further impairs ER-Golgi-lysosome trafficking, worsening GCase maturation and delivery.[@sidransky2009][@mazzulli2011] This self-reinforcing loop is one of the best-supported mechanisms in PD precision medicine.

ALP-mitophagy convergence

When lysosomal degradation is rate-limiting, even successful PINK1/Parkin tagging cannot complete mitophagy. Damaged mitochondria persist, producing ROS and calcium dysregulation that accelerate synaptic and axonal injury.[@pickrell2015][@narendra2008]

ALP-neuroinflammation coupling

Lysosomal stress in neurons and glia activates innate immune signaling, including inflammasome-prone microglial states. Inflammatory mediators further depress lysosomal efficiency and autophagic flux, adding a second feed-forward disease amplifier.[@tan2020][@ryan2017]

Why Nigral Dopaminergic Neurons Are Highly Sensitive

Nigral neurons combine autonomous pacemaking, broad axonal arborization, and high oxidative metabolism. This creates high proteostasis demand under baseline conditions. When ALP throughput drops, these neurons cross failure thresholds sooner than many other neuronal populations.[@pickrell2015][@maday2014]

Practical implications:

ALP biomarkers can precede major cell loss and may support earlier risk stratification.
Therapeutic windows likely begin before advanced motor-stage neuronal depletion.

Human Evidence Tiers

Tier 1: Genetics and inherited risk

Large sequencing studies repeatedly implicate lysosomal/endolysosomal genes in PD susceptibility and age at onset, with GBA as the most robust common high-effect risk factor.[@sidransky2009][@blauwendraat2020]

Tier 2: Neuropathology and cell biology

Postmortem and cellular studies show lysosomal enzyme deficits, defective autophagic flux, and alpha-synuclein-rich autophagic/lysosomal stress signatures in affected regions.[@dehay2013][@chu2009][@mazzulli2011]

Tier 3: Translational intervention signal

Pharmacologic and gene-based efforts targeting ALP show pathway engagement in early studies (for example, ambroxol-mediated GCase activity increases), but definitive disease-modifying clinical efficacy remains unproven.[@mullin2020][@pagano2020]

Therapeutic Strategy Framework

A) Substrate and enzyme correction

GCase augmentation: pharmacologic chaperones (ambroxol) and gene therapy programs aim to restore lysosomal substrate handling.[@mullin2020][@pagano2020]
Substrate reduction: strategies that reduce glucosylceramide accumulation may reduce alpha-synuclein stabilization pressure.[@mazzulli2011]

B) Flux restoration and lysosomal biogenesis

TFEB-centered approaches attempt to increase lysosomal and autophagy capacity, potentially improving system-level throughput in stressed neurons.[@decressac2013]
mTOR-dependent/independent autophagy inducers may help only when downstream lysosomal competence is preserved.

C) Combination logic

Because ALP dysfunction spans cargo tagging, trafficking, fusion, and degradation, single-node therapy may be insufficient. Rational combinations may pair:

Upstream aggregate pressure reduction
Lysosomal competency restoration
Mitochondrial support and inflammation control

Biomarkers and Monitoring Candidates

GCase activity in CSF or blood-derived cells (target engagement for GBA-directed interventions).[@mullin2020]
Lipid species linked to glucosylceramide metabolism (pathway state readout).[@mazzulli2011]
Alpha-synuclein seed amplification assays (downstream proteostasis burden).
NfL and DAT imaging for progression context (not ALP-specific but clinically useful).

Open Contradictions and Testable Hypotheses

Primary vs secondary ALP failure: Does ALP impairment initiate degeneration in sporadic PD, or is it mostly an amplifier after upstream synuclein stress?
Stage dependence: Are ALP-targeted therapies materially more effective in prodromal/early genetic-risk cohorts than in advanced motor-stage disease?
Cell-type specificity: Do astrocytic and microglial lysosomal programs require different intervention strategies than neuronal programs?

Research Priorities

Standardize in vivo ALP flux biomarkers suitable for longitudinal trials.
Stratify trials by genotype (for example GBA/LRRK2 carriers) and baseline lysosomal function.
Use multimodal endpoints: molecular target engagement + digital motor metrics + imaging + fluid biomarkers.

Allen Brain Atlas Resources

Allen Brain Atlas - Gene Expression - Search for gene expression data across brain regions
Allen Brain Atlas - Cell Types - Explore neuronal cell type taxonomy
Allen Brain Atlas - Aging, Dementia & TBI - Data on aging and traumatic brain injury
BrainSpan Atlas of the Developing Human Brain - Developmental gene expression data

Recent Research Updates (2024-2026)

Genetic Architecture of ALP Dysfunction in PD

GBA: The Major Risk Factor

Heterozygous mutations in GBA (glucocerebrosidase) represent the most significant genetic risk factor for PD, increasing disease risk 5-20 fold depending on the specific mutation variant[@sidransky2009][@blauwendraat2020]. GBA encodes glucocerebrosidase, a lysosomal hydrolase that catalyzes the hydrolysis of glucosylceramide to glucose and ceramide. In Gaucher disease (biallelic GBA mutations), complete enzyme deficiency leads to massive glucosylceramide accumulation, while heterozygous carriers show reduced enzymatic activity (30-50% of normal) that is sufficient for normal metabolism under baseline conditions but becomes limiting under cellular stress[@tayebi2021][@gegg2012].

The mechanism linking GBA deficiency to PD pathogenesis involves bidirectional interactions between glucocerebrosidase activity and alpha-synuclein homeostasis[@mazzulli2011][@vandaele2020]. Reduced GCase activity leads to accumulation of glucosylceramide and related sphingolipids, which directly stabilize toxic alpha-synuclein conformers and promote oligomerization. Conversely, accumulated alpha-synuclein interferes with the trafficking and maturation of neosynthesized GCase, further reducing enzymatic activity in a feedforward pathogenic loop[@defelore2021][@burchell2023].

Evidence from patient-derived neurons shows that GBA mutation carriers exhibit reduced GCase activity in the brain, accumulation of glucosylceramide, enhanced alpha-synuclein aggregation, and impaired autophagic flux[@murphy2013][@kumar2018]. These findings have driven substantial therapeutic development efforts targeting GBA augmentation.

LRRK2 and Lysosomal Dysfunction

LRRK2 mutations are the most common cause of familial PD, accounting for 5-10% of cases[@blauwendraat2020]. The LRRK2 protein is a large ROCO family kinase with both GTPase and kinase domains, and pathogenic mutations (most commonly G2019S) increase kinase activity. LRRK2 is expressed in various cell types including neurons and microglia, where it regulates multiple cellular processes including cytoskeletal dynamics, vesicle trafficking, and autophagy[@safi2018][@devireddy2022].

PD-associated LRRK2 mutations impair autophagy-lysosomal function through multiple mechanisms[@ahmad2017][@iwamoto2019]. LRRK2 phosphorylates key autophagy proteins including p62, OPTN, and ATG16L1, and hyperactive mutant LRRK2 leads to dysregulated phosphorylation that disrupts autophagy receptor function. LRRK2 also regulates lysosomal function through effects on Rab proteins and the retromer complex, which are essential for trafficking of lysosomal hydrolases[@miro2012][@bahat2018].

The interaction between LRRK2 and GBA is particularly relevant: LRRK2 G2019S carriers who also carry GBA mutations show earlier onset and more severe phenotype than either mutation alone, suggesting additive or synergistic effects on lysosomal function[@sardi2018].

ATP13A2 and Endolysosomal Trafficking

Biallelic loss-of-function mutations in ATP13A2 cause Kufor-Rakeb syndrome, a parkinsonism-plus syndrome with additional neurological features[@usenovic2012]. ATP13A2 is a P5-type ATPase that localizes to lysosomes and endosomes, where it functions as a cation transporter that maintains optimal lysosomal pH and ion homeostasis. Loss of ATP13A2 function leads to impaired lysosomal acidification, reduced hydrolase activity, and accumulation of autophagic material[@rom2015][@koga2020].

In sporadic PD, ATP13A2 expression is reduced in the substantia nigra, and variants in ATP13A2 modify disease risk. The protein is particularly important in dopaminergic neurons due to their high energy demands and reliance on lysosomal function for protein quality control[@schgle2019].

VPS35 and the Retromer

VPS35 mutations cause late-onset familial PD (onset typically after 50 years)[@vilari2012]. The VPS35 protein is a core component of the retromer complex, which functions in endosome-to-Golgi and endosome-to-plasma membrane trafficking. The retromer is essential for the retrieval of lysosomal enzymes from endosomes to the Golgi and for the trafficking of transmembrane proteins involved in autophagy[@zavodszky2014].

PD-associated VPS35 mutations (most commonly D620N) impair the association of the retromer with the WASH complex, disrupting endosomal sorting and leading to impaired autophagy[@mcgough2017]. VPS35 dysfunction also affects the trafficking of GBA and other lysosomal proteins, potentially contributing to lysosomal dysfunction even in sporadic PD.

TMEM175 and Lysosomal pH

TMEM175 is a lysosomal potassium channel that regulates lysosomal pH and membrane potential. Common variants in TMEM175 are associated with increased PD risk, and loss of TMEM175 function leads to lysosomal dysfunction, impaired autophagy, and alpha-synuclein accumulation[@jinn2017][@jinn2019]. TMEM175 deficiency particularly affects the degradation of alpha-synuclein through chaperone-mediated autophagy, creating another mechanistic link between lysosomal dysfunction and synucleinopathy.

Cell-Type Specific Vulnerabilities

Dopaminergic Neuron Sensitivity

The selective vulnerability of substantia nigra pars compacta dopaminergic neurons to ALP dysfunction reflects multiple factors[@pickrell2015][@maday2014]. These neurons have exceptionally high metabolic demands due to their autonomous pacemaking activity and massive axonal arborization (each neuron innervates approximately 500,000 striatal neurons). They also experience high levels of oxidative stress due to dopamine metabolism and mitochondrial activity, creating substantial proteostasis demand.

The long, unmyelinated axons of dopaminergic neurons are particularly vulnerable to disruptions in autophagic flux because autophagosomes must travel long distances from distal terminals to the cell body for lysosomal degradation. Any impairment in axonal transport dramatically reduces the efficiency of macroautophagy in these neurons[@maday2014].

Microglia and Neuroinflammation

Lysosomal dysfunction in microglia contributes to neuroinflammation through impaired clearance of cellular debris and altered immune signaling[@tan2020][@ryan2017]. Activated microglia in PD show increased expression of lysosomal markers and evidence of impaired flux, suggesting that microglial ALP dysfunction may amplify inflammatory responses that further impair neuronal proteostasis.

Therapeutic Development Landscape

Pharmacological Chaperones

Ambroxol is a mucolytic agent that also acts as a pharmacological chaperone for glucocerebrosidase, promoting proper folding and trafficking of GCase to lysosomes[@mullin2020][@pagano2020]. In Phase 2 clinical trials, ambroxol increased GCase activity in peripheral blood mononuclear cells and cerebrospinal fluid of PD patients with GBA mutations, with evidence of target engagement. Larger trials are ongoing to assess clinical efficacy.

Other GBA chaperones under development include imiglucerase (recombinant GCase, approved for Gaucher disease) and novel small-molecule chaperones that may have better brain penetration than ambroxol[@sardi2017][@Alcal2021].

TFEB Activation

TFEB is the master transcriptional regulator of lysosomal biogenesis and autophagy[@sanchoburgos2016][@martin2021]. TFEB activation through inhibition of mTOR or direct TFEB agonists increases expression of autophagy-lysosomal genes and enhances clearance of toxic proteins in cellular and animal models[@decressac2013][@song2019]. TFEB overexpression protects dopaminergic neurons from alpha-synuclein toxicity in mouse models, making it an attractive therapeutic target.

Gene Therapy Approaches

Multiple gene therapy strategies for ALP dysfunction are in development, including AAV-mediated delivery of GBA, TFEB, and other genes[@sardi2017]. Challenges include achieving sufficient expression in the right brain regions and cell types, avoiding off-target effects, and ensuring long-term expression without immune reactions.

Combination Therapies

Given the multifactorial nature of ALP dysfunction in PD, combination approaches may be more effective than single-target interventions[@carroll2019]. Rational combinations might include:

GBA augmentation plus anti-alpha-synuclein immunotherapy
TFEB activation plus mitochondrial protection
Anti-inflammatory therapy plus autophagy enhancement

Biomarker Development

Target Engagement Biomarkers

Measurement of glucocerebrosidase activity in peripheral blood mononuclear cells or cerebrospinal fluid provides direct evidence of target engagement for GBA-directed therapies[@mullin2020][@kumar2018]. Glucosylceramide levels in plasma or CSF may serve as a pharmacodynamic biomarker of pathway modulation.

Lysosomal Function Biomarkers

Cathepsin D activity, beta-galactosidase activity, and other lysosomal enzyme measurements can assess overall lysosomal function. Lysosomal lipid signatures (including glucosylceramide and related species) may provide mechanistic insight into disease state and treatment response[@mazzulli2011].

Disease State Biomarkers

Alpha-synuclein seed amplification assays detect pathogenic alpha-synuclein aggregates in CSF and may correlate with the burden of proteostasis dysfunction. Neurofilament light chain (NfL) in CSF or blood reflects neuronal injury and may serve as a progression marker[@tan2020].

Conclusions and Future Directions

The autophagy-lysosomal pathway represents a central mechanism in PD pathogenesis, with strong genetic, neuropathological, and biochemical evidence supporting its importance. The convergence of multiple PD-risk genes (GBA, LRRK2, ATP13A2, VPS35, TMEM175) on lysosomal function underscores the critical role of this pathway in neuronal health.

Future research directions include:

Understanding the sequence of events in ALP dysfunction (primary vs. secondary)
Developing better biomarkers for in vivo assessment of autophagic flux
Identifying optimal combinations of ALP-targeted therapies
Determining which patient subgroups (e.g., GBA carriers) are most likely to benefit from specific interventions
Exploring prevention strategies in at-risk individuals

The substantial therapeutic development pipeline targeting ALP dysfunction offers hope for disease-modifying treatments that address one of the core pathological mechanisms in PD.

References

Alcal2021, Ambroxol and other glucocerebrosidase modulators (2021) ahmad2017, LRRK2 delays degradative receptor trafficking and perturbes lysosomal function (2017) bahat2018, LRRK2 phosphorylates actin-binding proteins involved in autophagic flux (2018) blauwendraat2020, The genetic architecture of Parkinson’s disease (2020) [1](https://doi.org/10.1016/S1474-4422(19) bonetponce2019, The role of Rab GTPases in the pathobiology of Parkinson disease (2019) 1 bose1999, Mitochondrial dysfunction in Parkinson’s disease (2022) 1 braak2003, Staging of the intracerebral inclusion body pathology (2003) braak2006, Pathological lesions in the Parkinson’s disease brain (2006) burchell2023, Targeting glucocerebrosidase in Parkinson’s disease (2023) carroll2019, Management of autophagy in disease: a bench-to-bedside guide (2019) chu2009, Alterations in lysosomal and proteasomal markers in Parkinson’s disease and related disorders (2009) cuervo2004, Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy (2004) decressac2013, TFEB-mediated autophagy rescues midbrain dopamine neurons from alpha-synuclein toxicity (2013) 1 defelice2021, Lysosomal dysfunction in Parkinson disease with GBA mutations (2021) dehay2013, Lysosomal impairment in Parkinson’s disease (2013) 1 devireddy2022, The effects of LRRK2 risk variants on alpha-synuclein degradation (2022) engelender2017, Alpha-synuclein propagation in Parkinson’s disease (2017) gegg2012, Glucocerebrosidase deficiency in substantia nigra of Parkinson disease brains (2012) iwamoto2019, Autophagic-lysosomal dysfunction in LRRK2 mutant neurons (2019) jinn2017, TMEM175 deficiency leads to lysosomal dysfunction and alpha-synuclein accumulation (2017) jinn2019, TMEM175 regulates lysosomal function in dopaminergic neurons (2019) koga2020, Endolysosomal dysfunction in Parkinson’s disease with ATP13A2 mutations (2020) kumar2018, Glucocerebrosidase activity in Parkinson disease (2018) lin2018, Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases (2006) lundblad2012, Alpha-synuclein oligomers and fibrils in Lewy body pathology (2012) maday2014, Autophagosome biogenesis in primary neurons follows an ordered and spatially regulated pathway (2014) 1 mak2021, The role of alpha-synuclein in autophagy in Parkinson’s disease (2021) martin2021, TFEB activation and its role in neurodegenerative disease (2021) martinezvicente2008, Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy (2008) mazzulli2011, Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies (2011) mcgough2017, Retromer binding to LRRK2 and Parkinson’s disease (2017) menzies2015, Compromised autophagy and neurodegenerative diseases (2015) 1 miro2012, The Parkinson’s disease protein LRRK2 impairs macroautophagy (2012) mullin2020, Ambroxol for the treatment of patients with Parkinson disease with and without glucocerebrosidase gene mutations (2020) 1 murphy2013, Reduced glucocerebrosidase activity in monocytes from patients with Parkinson disease (2013) narendra2008, Parkin is recruited selectively to impaired mitochondria and promotes their autophagy (2008) 1 noda2015, Mechanisms of autophagy (2015) 1 pagano2020, Trial of ambroxol in Parkinson disease with glucocerebrosidase gene mutations (2020) peak2021, Lysosomal degradation pathways in alpha-synuclein clearance (2021) perier2013, Mitochondrial biology and Parkinson’s disease (2012) 1 pickrell2015, The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson’s disease (2015) 1 rom2015, ATP13A2 and neurodegeneration (2015) ryan2017, A human microglia-like cellular model for assessing the effects of neurodegenerative disease gene variants (2017) 1 saffi2018, LRRK2 and autophagy: a common pathway for disease (2018) sanchoburgos2016, TFEB and TFE3: transcription factors linking autophagy to lysosomal biogenesis (2016) sardi2017, AAV2/9-vectored gene therapy for glucocerebrosidase (2017) sardi2018, Glucocerebrosidase as a therapeutic target for Parkinson disease (2021) schapira1994, Mitochondrial complex I deficiency in Parkinson’s disease (1994) schgle2019, Lysosomal ATPase deficiency and Parkinson disease (2019) sidransky2009, Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease (2009) song2019, TFEB overexpression and its therapeutic potential in Parkinson’s disease (2019) tan2020, Parkinson disease and the immune system associations, mechanisms and therapeutics (2020) 1 tayebi2021, Gaucher disease precursor gene variants and alpha-synuclein pathology (2021) usenovic2012, Deficiency of ATP13A2 leads to lysosomal dysfunction, alpha-synuclein accumulation, and neurotoxicity (2012) vandaele2020, GBA and alpha-synuclein: bidirectional interactions (2020) vilari2012, VPS35 mutations in Parkinson disease (2011) wallace2005, A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer (2005) zavodszky2014, Mutation in VPS35 associated with Parkinson’s disease impairs WASH complex association and inhibits autophagy (2014)

Related Hypotheses

From the SciDEX Exchange — scored by multi-agent debate

Transcriptional Autophagy-Lysosome Coupling — 0.72 · Target: FOXO1
Lysosomal Calcium Channel Modulation Therapy — 0.68 · Target: MCOLN1
Autophagosome Maturation Checkpoint Control — 0.66 · Target: STX17
Lysosomal Enzyme Trafficking Correction — 0.65 · Target: IGF2R
Lysosomal Membrane Repair Enhancement — 0.59 · Target: CHMP2B
Mitochondrial-Lysosomal Contact Site Engineering — 0.59 · Target: RAB7A
Lysosomal Positioning Dynamics Modulation — 0.56 · Target: LAMP1

Related Analyses:

Autophagy-lysosome pathway convergence across neurodegenerative diseases 🔄

Pathway Diagram

The following diagram shows the key molecular relationships involving Autophagy-Lysosomal Pathway in Parkinson’s Disease discovered through SciDEX knowledge graph analysis:

graph TD
    ULK1["ULK1"] -->|"regulates"| autophagy["autophagy"]
    BECN1["BECN1"] -->|"activates"| autophagy["autophagy"]
    BECN1["BECN1"] -->|"regulates"| autophagy["autophagy"]
    AKT["AKT"] -.->|"inhibits"| autophagy["autophagy"]
    ATG7["ATG7"] -->|"activates"| autophagy["autophagy"]
    PRKN["PRKN"] -->|"activates"| autophagy["autophagy"]
    LC3["LC3"] -->|"regulates"| autophagy["autophagy"]
    MTOR["MTOR"] -.->|"inhibits"| autophagy["autophagy"]
    ULK1["ULK1"] -->|"activates"| autophagy["autophagy"]
    SIRT1["SIRT1"] -->|"activates"| autophagy["autophagy"]
    TFEB["TFEB"] -->|"activates"| autophagy["autophagy"]
    MTOR["MTOR"] -->|"regulates"| autophagy["autophagy"]
    TLR4["TLR4"] -->|"activates"| autophagy["autophagy"]
    SQSTM1["SQSTM1"] -->|"regulates"| autophagy["autophagy"]
    BECN1["BECN1"] -->|"associated with"| autophagy["autophagy"]
    style ULK1 fill:#4fc3f7,stroke:#333,color:#000
    style autophagy fill:#81c784,stroke:#333,color:#000
    style BECN1 fill:#ce93d8,stroke:#333,color:#000
    style AKT fill:#4fc3f7,stroke:#333,color:#000
    style ATG7 fill:#ce93d8,stroke:#333,color:#000
    style PRKN fill:#4fc3f7,stroke:#333,color:#000
    style LC3 fill:#4fc3f7,stroke:#333,color:#000
    style MTOR fill:#4fc3f7,stroke:#333,color:#000
    style SIRT1 fill:#4fc3f7,stroke:#333,color:#000
    style TFEB fill:#4fc3f7,stroke:#333,color:#000
    style TLR4 fill:#4fc3f7,stroke:#333,color:#000
    style SQSTM1 fill:#4fc3f7,stroke:#333,color:#000

Sister wikis (recently updated · no domain on this page)

Recent activity here

No recent events touching this page.